Convatec Share Discussion Threads

[hazl] 24/7/2018 08:37

Surely this is a little beauty!
And look who's bought in........,,,,,,,,

[citytrader66] 06/7/2018 19:19

close 189.65

comments?

[robow] 25/5/2018 10:35

Money Observer

ConvaTec is one of the main global players in ostomy and wound care, oligopolistic markets with little competitive pressure. Despite these attractions the shares have been weak this past year because of operational issues and a profit warning last October. Yet the firm will be a long-term winner as structural shifts in disease patterns and an ageing population ensure growing demand for its services. Sound financials and high profit margins just make the business even more appealing. 225.25p

[robow] 20/2/2018 08:12

Buy Convetec for recovery,says Share Centre
Strong full-year results from medical technology company Convatec (CTEC) boosted the shares but they are still a ‘long way’ from their highs and remain a buying opportunity, believes The Share Centre.

Analyst Helal Miah retained his ‘buy’ recommendation for ‘investors seeking a recovery potential and willing to accept a higher level of risk’ following last week’s results saw the shares rally 7%. They dipped 1%, or 2.3p, to 213p on Monday.

‘Overall the group has shown some positive progress, it operates in a defensive market with significant growth opportunities,’; said Miah.

‘While the shares are a long way off from its highs, we believe this is a growth opportunity to pick up these shares for the long term.’

He added that the underlying market for Convatec is ‘defensive in nature, but growth opportunities exist from ageing populations, the increased prevalence of chronic conditions, and the fact that patients are living longer with these conditions’.

[karateboy] 06/11/2017 19:55

UBS has upgraded CTEC to buy. This hopefully is the begining of share recovering some of its loses.

[mbmiah] 03/11/2017 15:03

This is getting battered - RSI is ripe for jump in share price ....takeover territory I reckon.

[citytrader66] 01/11/2017 19:00

RNS..release after 3pm this afternoon, i missed it!

CFO has purchased 100,000 shares.

On 30 and 31 October 2017 Frank Schulkes, the Company's Chief Financial Officer and a PDMR, purchased Shares in the Company as follows;
30 October 2017 - 50,000 Shares at £2.014399 per share.
31 October 2017 - 50,000 Shares at £1.959335 per share.
Mr Schulkes' resulting shareholding is 100,000 Shares.

[analyzer] 23/10/2017 13:28

Daily Mail/This is Money : 19 October 2017

DIRECTOR'S DEALS: Convatec chairman Sir Christopher Gent buys nearly £83,000 worth of shares

City grandee Sir Christopher Gent spent nearly £83,000 buying shares in Convatec after it lost more than a fifth of its value in a day.
In a vote of confidence in the medical products firm, the chairman bought 38,889 shares at 213p.
That followed a 26.6 per cent slump in the share price on Monday, after Convatec slashed its sales forecasts for the year amid supply issues and disappointing revenues.
Gent is a former chief executive of Vodafone and an ex-chairman of GlaxoSmithKline.

Read more:

[citytrader66] 16/10/2017 22:58

i think it will trade in a +-10p range for a few days or even weeks before some recovery. i bought today at 203.50p one minute before the close!

[polecat70] 16/10/2017 22:24

Does anyone think this is a good buy at its current price, or will it drop more tomorrow?

[citytrader66] 16/10/2017 22:16

RSI 14.97 indicates oversold?

[mbmiah] 16/10/2017 21:29

6 month RSI still indicates more selling to come

[montyhedge] 16/10/2017 19:19

Any company who disappoints get smashed, 185p my target.

[pugugly] 16/10/2017 15:02

Private investors stuffed yet again - Take care when Private Equity houses sell down - They normally know what they are doing and have seen rough water in the near or middle future (imo)

[peterbill] 16/10/2017 14:46

FY2017 guidance and third quarter update

16 OCTOBER 2017 (LSE: CTEC)



ConvaTec Group Plc ("the Group") is today providing an update on trading in the third quarter and revising guidance for full year expectations for organic revenue growth and delivery of the Margin Improvement Programme ("MIP Programme").



In the third quarter, Group revenue was $445.5 million, reflecting 6.8% reported growth on the same period in 2016, 5.1%[1] at constant exchange rates and 3.3%[2] organic growth. The Group also continued to expand its product portfolio across products and geographies. However, performance during the third quarter was severely impacted by supply issues in both Advanced Wound and Ostomy Care, and a lower than anticipated revenue contribution from new products.



Consequently, the Group now anticipate full year organic revenue growth will be between 1% and 2%, with the outcome in this range being dependent on the degree of success in resolving remaining supply issues, fulfilment of backorders and recovery of orders in both Advanced Wound and Ostomy Care in the fourth quarter.


RNS link below ...

[gswredland] 15/9/2017 17:18

So what are the main worries for investors guys?

[keyno] 15/9/2017 16:08

I think we will.

I sold out for small profit a few weeks ago. First bought in at 247 then made mistake, as it turned out of averaging up. Still think long-term will be a good investment once debt levels are reduced and if I still held my original purchase only I would probably have hung on. Probably. GLA.

[mbmiah] 15/9/2017 14:42

250 if you can get it

[gateside] 15/9/2017 13:16

Chart looking very weak. Might head back to the price it was floated at. Which I believe was around 230p

[keyno] 15/9/2017 11:04

Is 250 still a good entry point?

[gateside] 06/9/2017 21:55

Also they face strong competition from SN. in the advanced wound care market.

[gateside] 06/9/2017 21:53

Q1 results for 2017, saw operating profits fall by 8.5%

[mbmiah] 06/9/2017 19:49

No idea. This is just a quiet, boring old stock in the wrong direction I'm afraid. Just have to wait for the U-turn.

[gswredland] 06/9/2017 16:07

Well looks as if 250 is on it's way guys!
Any ideas as to why it is falling?